LUMENHANCE
LOE ApproachingNDAORALFOR SOLUTION
Approved
Dec 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LUMENHANCE is an oral solution approved by Bracco in December 1997 as an NDA product. The mechanism of action and specific indications are not disclosed in available data, limiting clarity on its therapeutic purpose. This legacy product operates in a mature market with moderate competitive pressure.
LOE Approaching
As a legacy product approaching loss of exclusivity, the commercial team is likely in maintenance mode with focus on managed decline rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job postings indicate this product is not a hiring priority for Bracco; career opportunities are severely limited. Employment on LUMENHANCE typically involves defensive commercial roles focused on volume retention and cost management rather than market expansion.
Brand ManagerField Sales Representative
Worked on LUMENHANCE at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.